Literature DB >> 15146093

Androgen replacement in men with hypogonadism and erectile dysfunction.

Marion Albrecht-Betancourt1, Rabih A Hijazi, Glenn R Cunningham.   

Abstract

The prevalence of hypogonadism and erectile dysfunction (ED) increases with age. Hypogonadism also is frequently associated with decreased libido and ED. Testosterone replacement therapy for hypogonadal ED is effective in restoring sexual desire and erectile function, especially in younger and healthy men. It appears to be less effective in older men with comorbid diseases that may cause ED. Therapy should be individualized, considered carefully, and closely monitored because of potential risks, especially in older men. The FDA has approved several testosterone delivery systems. These include a buccal testosterone tablet, intra-muscular injections, transdermal and subcutaneous forms. There also are several promising experimental androgens under investigation including non-steroidal selective androgen receptor modulators (SARMs). Copyright 2004 Humana Press Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15146093     DOI: 10.1385/ENDO:23:2-3:143

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  46 in total

1.  Sites in the male primate brain at which testosterone acts as an androgen.

Authors:  R P Michael; H D Rees; R W Bonsall
Journal:  Brain Res       Date:  1989-11-13       Impact factor: 3.252

2.  The relationship of serum testosterone to erectile function in normal aging men.

Authors:  Ernani Luis Rhoden; Claudio Telöken; Paulo Roberto Sogari; Carlos Ary Vargas Souto
Journal:  J Urol       Date:  2002-04       Impact factor: 7.450

3.  Serum androgenic hormones motivate sexual behavior in adolescent boys.

Authors:  J R Udry; J O Billy; N M Morris; T R Groff; M H Raj
Journal:  Fertil Steril       Date:  1985-01       Impact factor: 7.329

4.  Sexual dysfunction in the United States: prevalence and predictors.

Authors:  E O Laumann; A Paik; R C Rosen
Journal:  JAMA       Date:  1999-02-10       Impact factor: 56.272

5.  Testosterone replacement with transdermal therapeutic systems. Physiological serum testosterone and elevated dihydrotestosterone levels.

Authors:  G R Cunningham; E Cordero; J I Thornby
Journal:  JAMA       Date:  1989-05-05       Impact factor: 56.272

6.  Fetal phallic growth and penile standards for newborn male infants.

Authors:  K W Feldman; D W Smith
Journal:  J Pediatr       Date:  1975-03       Impact factor: 4.406

7.  Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma.

Authors:  J F Dunn; B C Nisula; D Rodbard
Journal:  J Clin Endocrinol Metab       Date:  1981-07       Impact factor: 5.958

8.  Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction.

Authors:  Antonio Aversa; Andrea M Isidori; Giovanni Spera; Andrea Lenzi; Andrea Fabbri
Journal:  Clin Endocrinol (Oxf)       Date:  2003-05       Impact factor: 3.478

9.  Effects of endogenous testosterone and estradiol on sexual behavior in normal young men.

Authors:  C J Bagatell; J R Heiman; J E Rivier; W J Bremner
Journal:  J Clin Endocrinol Metab       Date:  1994-03       Impact factor: 5.958

10.  Liver damage from long-term methyltestosterone.

Authors:  D Westaby; S J Ogle; F J Paradinas; J B Randell; I M Murray-Lyon
Journal:  Lancet       Date:  1977-08-06       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.